OBJECTIVE:Acute otitis media (AOM) is the most common complication of pediatric influenza, and imposes a substantial health care burden. We examined the influence of oseltamivir treatment on the incidence and course of AOM in children with influenza. METHODS: In the original study, 695 children 1-12 years who presented within 48h of the onset of influenza-like symptoms were randomized to oseltamivir (2mg/kg) or placebo given twice daily for 5 days. AOM was assessed at enrollment and days 3, 6 (+/-1), 10 (+/-2) and 28 (+/-7). AOM was clinically diagnosed by the participating primary care provider, supported by tympanometry when possible. We performed a retrospective analysis of those participants with laboratory-confirmed influenza (LCI). Assessments included the incidence and clinical course of new AOM cases. RESULTS: In all, 452 children had LCI; 217 receivedoseltamivir and 235 placebo. AOM was diagnosed on or after study day 3 at a significantly lower frequency in the oseltamivir versus placebo group (12.4% versus 21.7%; relative risk [RR]: 0.57 [95% CI: 0.37, 0.88], respectively). Treatment effects were greatest for children 1-2 years (RR=0.42 [95% CI: 0.20, 0.89]) and 3-5 years (RR=0.45 [95% CI: 0.19, 1.04]), in whom the incidence of AOM was highest. CONCLUSIONS:Oseltamivir treatment significantly reduces the emergence of new AOM infections in children with LCI; effects are most pronounced in those <5 years. CLINICAL TRIAL NUMBER: WV15758. Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved.
RCT Entities:
OBJECTIVE: Acute otitis media (AOM) is the most common complication of pediatric influenza, and imposes a substantial health care burden. We examined the influence of oseltamivir treatment on the incidence and course of AOM in children with influenza. METHODS: In the original study, 695 children 1-12 years who presented within 48h of the onset of influenza-like symptoms were randomized to oseltamivir (2mg/kg) or placebo given twice daily for 5 days. AOM was assessed at enrollment and days 3, 6 (+/-1), 10 (+/-2) and 28 (+/-7). AOM was clinically diagnosed by the participating primary care provider, supported by tympanometry when possible. We performed a retrospective analysis of those participants with laboratory-confirmed influenza (LCI). Assessments included the incidence and clinical course of new AOM cases. RESULTS: In all, 452 children had LCI; 217 received oseltamivir and 235 placebo. AOM was diagnosed on or after study day 3 at a significantly lower frequency in the oseltamivir versus placebo group (12.4% versus 21.7%; relative risk [RR]: 0.57 [95% CI: 0.37, 0.88], respectively). Treatment effects were greatest for children 1-2 years (RR=0.42 [95% CI: 0.20, 0.89]) and 3-5 years (RR=0.45 [95% CI: 0.19, 1.04]), in whom the incidence of AOM was highest. CONCLUSIONS:Oseltamivir treatment significantly reduces the emergence of new AOM infections in children with LCI; effects are most pronounced in those <5 years. CLINICAL TRIAL NUMBER: WV15758. Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved.
Authors: Michael J Binks; Allen C Cheng; Heidi Smith-Vaughan; Theo Sloots; Michael Nissen; David Whiley; Joseph McDonnell; Amanda J Leach Journal: BMC Infect Dis Date: 2011-06-07 Impact factor: 3.090
Authors: Katherine A Poehling; Kathryn M Edwards; Marie R Griffin; Peter G Szilagyi; Mary A Staat; Marika K Iwane; Beverly M Snively; Cynthia K Suerken; Caroline B Hall; Geoffrey A Weinberg; Sandra S Chaves; Yuwei Zhu; Monica M McNeal; Carolyn B Bridges Journal: Pediatrics Date: 2013-01-06 Impact factor: 7.124
Authors: James R Smith; Craig R Rayner; Barbara Donner; Martina Wollenhaupt; Klaus Klumpp; Regina Dutkowski Journal: Adv Ther Date: 2011-11-01 Impact factor: 3.845
Authors: Leonid Gibiansky; Patanjali Ravva; Neil J Parrott; Rajinder Bhardwaj; Elke Zwanziger; Paul Grimsey; Barry Clinch; Stefan Sturm Journal: Clin Pharmacol Ther Date: 2020-02-26 Impact factor: 6.875
Authors: Jeffrey Baker; Stanley L Block; Balpreet Matharu; Laura Burleigh Macutkiewicz; Steffen Wildum; Sophie Dimonaco; Neil Collinson; Barry Clinch; Pedro A Piedra Journal: Pediatr Infect Dis J Date: 2020-08 Impact factor: 3.806